A Clinical Laboratory Model for Evaluating the Acute Effects of Electronic “Cigarettes”: Nicotine Delivery Profile and Cardiovascular and Subjective Effects
Top Cited Papers
- 1 August 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 19 (8), 1945-1953
- https://doi.org/10.1158/1055-9965.epi-10-0288
Abstract
Background: Electronic “cigarettes” are marketed to tobacco users as potential reduced exposure products (PREP), albeit with little information regarding electronic cigarette user toxicant exposure and effects. This information may be obtained by adapting clinical laboratory methods used to evaluate other PREPs for smokers. Methods: Thirty-two smokers participated in four independent Latin-square ordered conditions that differed by product: own brand cigarette, “NPRO” electronic cigarettes (NPRO EC; 18 mg cartridge), “Hydro” electronic cigarettes (Hydro EC; 16 mg cartridge), or sham (unlit cigarette). Participants took 10 puffs at two separate times during each session. Plasma nicotine and carbon monoxide (CO) concentration, heart rate, and subjective effects were assessed. Results: Own brand significantly increased plasma nicotine and CO concentration and heart rate within the first five minutes of administration whereas NPRO EC, Hydro EC, and sham smoking did not. Own brand, NPRO EC, and Hydro EC (but not sham) significantly decreased tobacco abstinence symptom ratings and increased product acceptability ratings. The magnitude of symptom suppression and increased acceptability was greater for own brand than for NPRO EC and Hydro EC. Conclusions: Under these acute testing conditions, neither of the electronic cigarettes exposed users to measurable levels of nicotine or CO, although both suppressed nicotine/tobacco abstinence symptom ratings. Impact: This study illustrates how clinical laboratory methods can be used to understand the acute effects of these and other PREPs for tobacco users. The results and methods reported here will likely be relevant to the evaluation and empirically based regulation of electronic cigarettes and similar products. Cancer Epidemiol Biomarkers Prev; 19(8); 1945–53. ©2010 AACR.Keywords
This publication has 31 references indexed in Scilit:
- Evaluating oral noncombustible potential-reduced exposure products for smokersNicotine & Tobacco Research, 2010
- Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administrationTobacco Control, 2010
- Waterpipe Tobacco and Cigarette Smoking: Direct Comparison of Toxicant ExposureAmerican Journal of Preventive Medicine, 2009
- Measures for Assessing Subjective Effects of Potential Reduced-Exposure ProductsCancer Epidemiology, Biomarkers & Prevention, 2009
- Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure ProductsCancer Epidemiology, Biomarkers & Prevention, 2009
- Test marketing of new smokeless tobacco products in four U.S. citiesNicotine & Tobacco Research, 2009
- Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokersTobacco Control, 2009
- Potential reduced exposure products (PREPs) for smokeless tobacco users: Clinical evaluation methodologyNicotine & Tobacco Research, 2008
- Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokersNicotine & Tobacco Research, 2008
- Transdermal nicotine-induced tobacco abstinence symptom suppression: Nicotine dose and smokers' gender.Experimental and Clinical Psychopharmacology, 2006